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Abstract: The anti-inflammatory cytokine Interleukin-10 (IL-10) is considered an efficient treatment
for corneal inflammation, in spite of its short half-life and poor eye bioavailability. In the present work,
mRNA-based nanomedicinal products based on solid lipid nanoparticles (SLNs) were developed
in order to produce IL-10 to treat corneal inflammation. mRNA encoding green fluorescent protein
(GFP) or human IL-10 was complexed with different SLNs and ligands. After, physicochemical
characterization, transfection efficacy, intracellular disposition, cellular uptake and IL-10 expression of
the nanosystems were evaluated in vitro in human corneal epithelial (HCE-2) cells. Energy-dependent
mechanisms favoured HCE-2 transfection, whereas protein production was influenced by energy-
independent uptake mechanisms. Nanovectors with a mean particle size between 94 and 348 nm
and a positive superficial charge were formulated as eye drops containing 1% (w/v) of polyvinyl
alcohol (PVA) with 7.1–7.5 pH. After three days of topical administration to mice, all formulations
produced GFP in the corneal epithelium of mice. SLNs allowed the obtaining of a higher transfection
efficiency than naked mRNA. All formulations produce IL-10, and the interleukin was even observed
in the deeper layers of the epithelium of mice depending on the formulation. This work shows the
potential application of mRNA-SLN-based nanosystems to address corneal inflammation by gene
augmentation therapy.
Keywords: messenger RNA; solid lipid nanoparticles; interleukin-10; corneal inflammation; polyvinyl
alcohol; topical administration; gene augmentation; transfection; corneal epithelium; advanced therapies
1. Introduction
The eye is considered the perfect target for gene therapy due to its physiological
features: it is easy to access and examine, it has a well-defined anatomy and it is relatively
immune privileged. Moreover, from an experimental point of view, in the same subject,
one eye can be used as a control, whereas the other eye can be used as the experimental
target [1–3]. Currently, 47 clinical trials restricted to “ocular diseases” are registered
in the database of Gene Therapy Clinical Trials Worldwide [4], all of them targeting
retinal degenerative diseases, except one, which concerns corneal opacity. The cornea
is a transparent tissue localized in the anterior segment of the eye, which contributes to
eyesight by focusing a visual image through light refraction. Several factors can damage
this tissue and provoke corneal inflammation or keratitis, such as infections, dry eye, eyelid
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disorders, physical and chemical damage, and a wide variety of underlying diseases [5].
Current treatments of corneal inflammation are based on corticosteroids, which require
repeated topical applications and have been associated with multiple adverse effects, such
as infectious keratitis, increased intraocular pressure, and cataracts [6]. Alternatively, the
topical administration of IL-10, an anti-inflammatory cytokine, has been suggested as an
effective treatment for corneal inflammation [7]. However, the short half-life and poor eye
bioavailability of IL-10 limit its therapeutic use. Therefore, IL-10 ocular delivery may be
better attempted by gene therapy, with the aim of inducing IL-10 de novo synthesis in
corneal cells [8].
In the last few decades, a wide range of reagents and techniques suitable to transfer
nucleic acids into cells have been developed, in order to modulate both in vitro and in vivo
gene expression. Particularly, mRNA therapeutics present several advantages: since mRNA
does not need to enter inside the cell nucleus in order to exert its effect, protein translation
is faster than in the case of DNA; furthermore, mRNA expression is temporary and it owns
a safe profile with no risk of insertion-related mutagenesis, as it does not incorporate into
the genome of the host [9]. Additionally, the production and manufacturing of mRNA is
easy to scale up in a cost-effective, standardized, and reproducible way. However, mRNA
instability is one of its major vulnerabilities [10], which makes the development of suitable
delivery systems necessary. Delivery systems should be able to protect mRNA against
RNase degradation, and to ensure its intracellular delivery inside the cytoplasm of the tar-
get cell [11]. In this context, different strategies and efforts for advances in nanotechnology
and material sciences are still ongoing [9]. Presently, non-viral vectors are at the frontline
of mRNA therapy, in contrast to DNA-based gene therapy; particularly, lipid-based vectors
are among the most extensively used non-viral nucleic acid delivery platforms. Indeed,
mRNA therapy has gained much attention after its application in the vaccination against
the SARS-CoV-2 [12–14]. It should be noted that during the COVID-19 pandemic, the
first vaccines approved for distribution and use against the SARS-CoV-2 by the European
Medicines Agency (EMA) and the United States Food and Drug Administration (FDA)
were based on mRNA encapsulated in lipid nanoparticles (LNs) [15,16]. These mRNA
vaccines have been well-tolerated and have demonstrated approximately 95% efficacy
against COVID-19, with few adverse events [17,18].
Among lipid-based systems, liposomes and solid lipid nanoparticles (SLNs) have been
suggested as up-and-coming non-viral ocular drug delivery systems. [19,20]. Liposomes
were introduced as carriers for the delivery of nucleic acids for gene therapy over two
decades ago and, to date, they still represent the most widely studied vectors for gene
delivery. Liposomes used for gene delivery are typically nanometric and are defined by a
spherical vesicle with an aqueous internal cavity enclosed by a lipid bilayer membrane.
However, these systems are not devoid of stability and efficacy issues [21,22]. SLNs were
more recently developed with the aim of, among other things, addressing the above
issues underlying liposome gene transfection [23]. SLNs are spherical particles with
a solid lipid core matrix, which is stabilized by surfactants in an aqueous dispersion,
and are usually composed of well-tolerated physiological lipids [24–27]. In addition,
SLNs have demonstrated to be effective for ocular topical drug administration [28]. This
administration route shows several advantages: it is non-invasive, drug absorption into
the systemic circulation is minimized, first pass metabolism is prevented, and formulations
are easy to administer. However, the main issue of conventional ocular drug delivery
systems relies on the poor retention onto the ocular surface, due to corneal clearance; as
a consequence, the amount of drug that is able to cross the cornea and access the ocular
structures is small. Therefore, an effective ocular drug delivery system should increase
corneal retention time and improve drug permeation through the cornea [29]. SLNs possess
a nanometer sized-range, lipophilic properties, and usually positive surface charges. This
makes them suitable for topical drug administration by improving corneal permeation and
retention [30,31]. Previously, our research group has used a gene augmentation strategy to
induce IL-10 production into the cornea by the administration of SLNs containing plasmid
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DNA (pDNA) [32]. However, mRNA could be an alternative therapeutic option to tackle
corneal inflammation, thanks to its high efficacy, safety profile, and versatility for fast
protein production.
The aim of this experimental work is the development of SLNs containing mRNA
as non-viral vectors, to be used as a genetic supplementation strategy for the de novo
production of IL-10 in corneal cells. Additionally, vectors prepared with plasmid DNA
(pDNA) were evaluated for comparison purposes. Formulations containing mRNA or
pDNA encoding green fluorescent protein (GFP) or IL-10 were characterized from a physico-
chemical point of view, and then evaluated for internalization and transfection properties,
both in vitro by using human corneal epithelial (HCE-2), and in vivo after administration to
mice by ocular instillation.
2. Materials and Methods
2.1. Materials
1,2-Dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) was obtained from
Avanti Polar-lipids, Inc. (Alabaster, AL, USA). Precirol® ATO 5 (glyceryl palmitostearate) was
kindly provided by Gattefossé (Madrid, Spain). Tween 80 and dichloromethane were pur-
chased from Panreac (Madrid, Spain) and sodium behenate from Nu-Chek Prep (Eleysian,
AL, USA). Sigma-Aldrich (Madrid, Spain) provided protamine sulfate salt from salmon
(Grade X) (P), dextran (Mn of 3260 Da) (DX), DEAE-dextran, Nile Red and partially hy-
drolyzed polyvinyl alcohol (PVA) 9000–10,000 Da Mw. Lifecore Biomedical (Chaska, MN,
USA) supplied hyaluronic acid (HA) (Mw of 100 KDa).
CleanCapTM EGFP mRNA (5moU) and CleanCapTM Cyanine 5 EGFP mRNA (5moU
were acquired from TriLink BioTechnologies (San Diego, CA, USA). Both of the nucleic
acids encode green fluorescent protein (GFP). mRNA encoding human IL-10 was cus-
tomized by TriLink BioTechnologies. Professor BHF Weber laboratory (University of
Regensburg, Germany) kindly provided plasmid pcDNA3-EGFP (6.1 kb) encoding GFP.
Plasmid pUNO1-hIL10 (3.7 kb), which encodes human IL-10, was acquired by InvivoGen
(San Diego, CA, USA). Label IT® Cy®5 Nucleic Acid Labeling Kit was obtained from Mirus
Bio (Madison, WI, USA).
Materials used on agarose gel in an electrophoresis assay were acquired from Bio-Rad
(Madrid, Spain). AmbionTM RNase I was purchased from Life Technologies (Thermo Fisher
Scientific, Madrid, Spain), Deoxyribonuclease I (DNase I) and sodium dodecyl sulfate (SDS)
from Sigma-Aldrich and GelRedTM from Biotium (Fremont, CA, USA).
Human Corneal Epithelial (HCE-2) cells were purchased from American Type Cul-
ture Collection (ATCC, Manassas, VA, USA). Cell culture reagents, including Dulbecco’s
Modified Eagle´s Medium/Nutrient Mixture F-12 with GlutaMAXTM (DMEM/F-12 with
GlutaMAXTM), fetal bovine serum (FBS), Penicillin-Streptomycin, Trypsin/EDTA and At-
tachment Factor were acquired from Life Technologies (Thermo Fisher Scientific, Madrid,
Spain), whereas epidermal Growth Factor (EGF) and human insulin solution were obtained
from Myltenyi Biotec (Madrid, Spain) and Sigma-Aldrich (Madrid, Spain), respectively.
The DuoSet Ancillary reagent kit and Enzyme-linked immunoassay (ELISA) for IL-10 were
obtained from R&D Systems (Minneapolis, MN, USA).
Reporter lysis buffer was provided by Promega Biotech Ibérica (Madrid, Spain).
Paraformaldehyde (PFA) was obtained from Panreac, while 40,6-diamidine-20-phenylindole
dihydrochloride (DAPI)-fluoromount-G was purchased from Southern Biotech (Birming-
ham, AL, USA). Phosphate buffered saline (PBS) and HEPES buffered solution were
obtained from Gibco (Thermo Fisher Scientific, Madrid, Spain) and LipofectamineTM
2000 Lipid-Reagent was acquired from Life Technologies (Thermo Fisher Scientific, Madrid,
Spain). The 7-Amino-Actinomycin D (7-AAD) Viability Dye was acquired from Beckman
Coulter (Brea, CA, USA).
Antibodies used for immunoassay, Anti-GFP polyclonal antibody and goat anti-Rabbit
IgG (H+L) Cross-Adsorbed Secondary Antibody Alexa Fluor 488, were provided by Life
Technologies (Thermo Fisher Scientific, Madrid, Spain), except rabbit Anti-IL-10 antibody,
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which was obtained from Abcam (Cambridge, UK). Sakura Finetek Europe (Alphen aan
den Rijn, The Netherlands) supplied Tissue-Tek® O.C.T.-compound.
Other chemicals, unless detailed, were reagent grade from Panreac (Barcelona, Spain)
and Sigma-Aldrich (Madrid, Spain).
2.2. Formulation of SLNs and Vectors
Three different techniques were used in order to prepare SLNs: solvent evapora-
tion/emulsification (SLNEE), hot-melt emulsification (SLNHM) and coacervation (SLNC).
SLNEE were elaborated as previously reported [33], with the solid lipid Precirol® ATO
5 and the cationic lipid DOTAP, stabilized by the surfactant Tween 80. Briefly, SLNEE were
obtained by the sonication (Branson Sonifier 250, Danbury) of the organic phase (Precirol®
ATO 5 dissolved in dichloromethane 5% w/v) in the aqueous phase, containing the cationic
lipid DOTAP (0.4% w/v) and Tween 80 (0.1% w/v). SLNs’ precipitation occurred upon
dichloromethane evaporation.
SLNHM was produced as a SLNEE with minor modifications. Briefly, DOTAP (0.4%
w/v) and Tween 80 (0.1% w/v) were dissolved in water. This aqueous solution and Precirol®
ATO 5 were heated in a bain-marie. When both phases were led to 80 ◦C and lipids melted,
the aqueous solution was added to the Precirol® ATO 5. The emulsion was obtained
by sonication (Branson Sonifier 250, Danbury, CT, USA) for 30 min at 50 W. SLNs were
obtained by cooling the obtained nanoemulsion on ice for 30 min.
SLNC were composed of behenic acid as the lipid matrix, coated by the suspending
agent PVA 9000 and the cationizing agent DEAE-dextran, as previously described [32].
Briefly, sodium behenate and PVA 9000 were dissolved in water under hot agitation,
and when the solution reached 80 ◦C and became translucent, NaOH was added. Then,
when the solution turned completely transparent DEAE-dextran was added drop by drop,
turning the mixture turbid. Later, HCl was rapidly added and when the suspension
turned white, it was cooled under stirring in a water bath. The final product underwent a
re-melting process, by heating again and cooling by agitation in a water bath.
When required, Nile Red was incorporated in the preparation of all SLNs to label them.
In the case of SLNEE, Nile Red was dissolved in the dichloromethane of the organic phase,
whereas in SLNHM Nile Red was dissolved in dichloromethane and added during the first
30 s of the sonication step. Finally, in the case of SLNC, a solution of dichloromethane
containing Nile Red was added during the re-melting step.
In order to prepare SLN-based vectors, an aqueous solution of protamine (P) was
added to the nucleic acid, mRNA or pDNA. Then, a solution of polysaccharide, dextran
(DX) or hyaluronic acid (HA) dissolved in water was added. Finally, the SLN suspension
was added to the previous complexes and incubated for 20 min. Electrostatic interactions
between negative and positive charges of the components led to the formation of the final
vectors, in which complexes were adsorbed on the surface of the cationic SLNs.
The weight ratios of the components of the formulations are summarized in Table 1.
Table 1. Weight ratios of the formulations.









SLN: Solid Lipid Nanoparticle. DX: dextran. HA: hyaluronic acid. P: protamine.
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In order to obtain viscous formulations suitable for ocular delivery to animal mod-
els, an aqueous solution of PVA (85,000–124,000 Mw) was incorporated into the above
mentioned vectors. The final concentration of PVA was 1% (w/v).
2.3. Characterization of SLNs and Vectors: Size, Polydispersity Index and ζ-Potential
Measurements
The mean size and polydispersity index (PDI) of 3 batches of SLNs and vectors were
measured by Dynamic Light Scattering (DLS) and ζ-potential was determined by Laser
Doppler Velocimetry (LDP). These measurements were carried out in a ZetaSizer Nano
ZS (Malvern Panalytical, Malvern, UK) after the appropriate dilution of the samples in
Milli-Q™ water (EDM Millipore, MA, USA).
2.4. Agarose Gel Electrophoresis Assay
Studies of mRNA binding capacity, protection from RNase I digestion and release
from the vectors were performed in a 1.2% agarose gel electrophoresis labelled with Gel
RedTM. The gel ran for 60 min at 75 V, then it was immediately analyzed with the Uvitec
Uvidoc D-55-LCD-20 M Auto transilluminator (Cambridge, UK). In order to evaluate
binding capacity, vectors were diluted in MilliQTM water to a final concentration of 0.12 µg
mRNA/µL in the gel. Protection from RNase I digestion was analyzed by the addition of
6 U RNase I/µg mRNA; mixtures were incubated at 37 ◦C for 40 min in a heater. Then, the
samples were removed from the heater and mixed with an SDS solution (final concentration
of 1%), at room temperature. The same SDS solution was added to the vectors to unbind
the mRNA in the release studies. Two controls for the integrity of the mRNA were included
in the assay: RiboRuler High Range RNA Ladder and untreated CleanCapTM EGFP mRNA
(5moU).
In order to study the pDNA binding capacity, protection against DNase I digestion
and release from the vectors, 0.7% agarose gel electrophoresis with Gel RedTM was used.
The gel was analyzed with the Uvitec Uvidoc D-55-LCD-20 M Auto transilluminator
(Cambridge, UK) after running for 30 min at 120 V. The binding capacity was evaluated
by adding vectors diluted in MilliQTM water to a final concentration of 0.03 µg pDNA/µL
in the gel. For DNAse I protection, the same concentration was exposed to 1 U DNase
I/2.5 µg pDNA and then incubated at 37 ◦C for 30 min in a heater. The samples were
removed from the heater and mixed with an SDS solution (4%) to a final concentration of
1% at room temperature. The same SDS solution was added to the vectors to unbind the
plasmid in the release studies. Two controls for the integrity of the pDNA were included
in the gels: 1 kb pDNA ladder from NIPPON Genetics Europe (Dueren, Germany) and
untreated pcDNA3-EGFP plasmid.
2.5. pH Measurement
Crison Basic 20 pH meter (Crison Instruments, Barcelona, Spain) was employed to
determine the pH of the vectors. Measures were carried out in triplicate and the pH meter
was calibrated daily.
2.6. Cell Culture Studies
Human corneal epithelial (HCE-2) cell line was used in order to perform in vitro
studies. HCE-2 cell line was maintained in a DMEM/F-12 GlutaMAXTM medium, which
was supplemented with 15% (v/v) heat-inactivated fetal bovine serum (FBS), insulin
(4 mg/mL), Epidermal Growth Factor (EGF) (10 ng/mL), and Penicillin–Streptomycin (1%
v/v) and incubated at 37 ◦C with 5% CO2. Cells were sub-cultured once a week using
Trypsin/EDTA in flasks earlier treated with Attachment Factor. The medium was renewed
every 2 days. Cells from passages 1 to 4 were used to perform all in vitro assays.
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2.6.1. Transfection Efficacy and Cell Viability
mRNA-based vectors were prepared 72 h before their addition and maintained at 4 ◦C
before their use.
After incubation with Attachment Factor, the cells were cultured on 24-well plates for
72 h at a density of 70,000 cells/well, until the cells were adhered and were able to create a
monolayer. Later, part of the medium was removed, leaving enough volume to cover the
cells, and a total volume of 75 µL of each vector diluted in Hank’s Balanced Salt solution
(HBS) (equivalent to 2.5 µg) was added to each well for 4 h in the incubator at 37 ◦C in a
5% CO2. The medium containing the vectors was removed after the incubation time, and
the cells were refreshed with 1 mL of the complete medium. The cells were kept growing
during 48 h or 72 h in the case of mRNA- or pDNA-vectors, respectively.
The percentage of transfected cells and intensity of fluorescence, indicative of the
amount of GFP produced, as well as cell viability, were measured using a CytoFLEX flow
cytometer (Beckman Coulter). For this purpose, the cells were washed with 500 µL of
PBS and then detached by incubation with 300 µL of Trypsin/EDTA for 5 min. After the
centrifugation of cell suspension at 1000 rpm for 5 min, the supernatant was removed,
and the pellet of cells was resuspended in 500 µL of PBS. Ten thousand events were
collected for each sample. Transfection efficacy was measured at 525 nm (FITC) [34], and
cell viability was determined at 610 nm (ECD), after the addition of 7-Amino-Actinomycin
D (7-AAD) Viability Dye to the samples. The percentage of transfected cells was calculated
counting the positive fluorescent GFP cells over the total cells. The intensity of fluorescence
represented the mean of the intensity of fluorescence per labelled cell, which is correlated
with gene expression and protein production [35–37].
The effect of temperature on cell transfection was studied by the incubation of HCE-2
cells at 4 ◦C for 30 min, prior to the addition of the vectors. The cells were maintained for
4 h at 4 ◦C, and then the cells were treated as explained above.
2.6.2. Cellular Uptake
The internalization of the vectors by the HCE-2 cells was studied by using vectors
containing SLNs labelled with the fluorescent Nile Red dye (λ = 590 nm), as previously
described [8] and as explained above. The vectors were prepared 72 h before their addition.
For this purpose, a total volume of 75 µL of each vector diluted in HBS (equivalent to
2.5 µg of nucleic acid) was added to each well; then, the cells were incubated for 2 h
at 37 ◦C in a 5% CO2. Once the incubation time had finished, the culture medium was
removed and the cells were detached from the plates, as described in Section 2.6.1, for
the cytometry analysis of transfected cells. The entrance of the vectors was analyzed by
using a CytoFLEX flow cytometer (Beckman Coulter) at 610 nm (ECD). For each sample,
10,000 events were collected.
Additionally, the effect of temperature on cellular uptake was studied by the incu-
bation of cells at 4 ◦C for 30 min before the incorporation of the vectors. Once the Nile
Red-labelled vectors were added to the cell cultures, the cells were maintained at 4 ◦C for
an additional 2 h. Finally, the cells were collected to evaluate the vector uptake by flow
cytometry, as described above. In this case, the percentage of positive cells corresponds to
the cells that have uptaken vectors labelled with Nile Red over the total cells.
2.6.3. Intracellular Disposition of the Vectors
A density of 150,000 cells in 1 mL per well was seeded in Millicell EZ slides (Millipore)
and incubated at 37 ◦C and 5% CO2 for 24 h. Then, they were treated with 75 µL of vector
equivalent to 0.8 µg of CleanCapTM Cyanine 5 EGFP mRNA (5moU) as nucleic acid. After
4 h, the slides were washed with PBS, fixed with PFA 4% and covered with the mounting
fluid DAPI-fluoromount-G™, used to label the nuclei. Then, a Leica DM IL LED Fluo
inverted microscope (Leica Microsystems CMS GmbH, Wetzlar, Germany) was used to
analyze the slides.
Pharmaceutics 2021, 13, 1472 7 of 22
2.6.4. Quantification of IL-10
To measure the levels of IL-10 expressed by the cells aft er the addition of the com-
plexes, an Enzyme-linked Immunosorbent Assay (ELISA) kit was carried out. The secreted
and intracellular IL-10 were quantified 48 h and 72 h after the addition of the mRNA-
and pDNA-bearing vectors encoding human IL-10, respectively. For the secreted IL-10,
the medium of each well was removed and centrifuged at 12,000× g for 2 min. For the
intracellular IL-10, the cells were washed with 300 µL of PBS twice, and then 400 µL of
reporter lysis buffer 1× was added. Finally, the plate was frozen to complete the lysis
of cell culture. After thawing, each well was detached by a scrapper and the lysate was
centrifuged at 12,000× g for 2 min at 4 ◦C. A total of 100 µL of each sample was added to a
96-well plate that was covered with the corresponding capture antibody; then the assay
was performed according to the manufacturer’s instructions.
2.7. In Vivo Studies
Five-week-old male BALB/cOlaHsd mice, with a weight ranging between 20 and 25 g
(Envigo), were employed for the in vivo studies.
The use of the mice (license M20/2018/142) was approved by The Animal Experimen-
tation Ethics Committee of the University of the Basque Country UPV/EHU following
the Spanish and European Union (EU) laws. All the procedures were followed in accor-
dance. The animals were accommodated under controlled temperature, humidity, and 12 h
day-night cycles, with food and water ad libitum access.
The mice were anesthetized with 1–2% isoflurane (IsoFlo, Abbott, Madrid, Spain) in
air, at a flow rate of 0.5–1 L/min with the aim of preventing distress during experimental
manipulation.
The mice were humanely euthanatized by cervical dislocation, and then their eyes
were removed. After the enucleation, the eyes were washed in a physiological saline
solution, fixed with 4% PFA during 30 min and washed with PBS for 5 min. Then, the eyes
were immersed in 30% sucrose in PBS at 4 ◦C until the eyes precipitated. Then, half of
the volume was removed and substituted with Tissue-Tek® O.C.T.TM and shaken at room
temperature for 2 h. Finally, the eyeballs were stored in 100% Tissue-Tek® O.C.T.TM to
freeze at 80 ◦C for future studies.
2.7.1. Topical Administration
The formulations described in Table 1, as well as naked mRNA encoding GFP or
human IL-10, were viscosized with 1% PVA (85,000–124,000 Mw), and administered to the
mice by eye drop instillation. The administration of the nanosystems was carried out in
2 doses over 3 days. In each dose, 3 instillations of 2.5 µL at 3 min intervals were carried
out, administering a final dose of 4.5 µg of nucleic acid per day.
2.7.2. Evaluation of Gene Expression
The mice were sacrificed 24 h or 48 h after the last dose depending on the formulation
administered. For GFP expression studies, the mice were sacrificed at 48 h, except in the
case of mRNA-HA-SLNEE formulation, where the mice were sacrificed both at 24 h and
48 h. For IL-10 expression studies, the mice were sacrificed at 24 h. Then, the eyeballs were
extracted, fixed and histologically evaluated by sections of 14 µm on a cryostat (Cryocut
3000, Leica, Bensheim, Germany).
In order to evaluate the gene expression, two different transfection studies were
carried out. In the first one, vectors contained the nucleic acid that encodes GFP, whereas in
the second one vectors were bearing the nucleic acid that encodes IL-10. Both transfections
were evaluated qualitatively by immunofluorescence. Sections were washed with a PB
buffer. The samples were blocked and permeabilized employing a solution of 20% PB,
0.3% Triton X-100, 10% goat serum, and water q.s. 100%. Then, the respective primary
antibody, anti-GFP or anti-IL-10, was added and incubated for 24 h at 4 ◦C. Secondary
antibody goat anti-rabbit IgG Alexa Fluor 488 was added in both transfection assays after
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washing for 30 min protected from light. Finally, after washing and drying the samples,
they were mounted with DAPI-Fluoromount-G. Tissue sections were examined by a Zeiss
LSM800 confocal microscope (ZEISS microscopy, Oberkochen, Germany). The overlapping
of fluorescence emission spectra was avoided by sequential acquisition. Six sections for
each cornea were analyzed as representations of the entire tissue.
2.8. Data Analysis
IBM SPSS Statistics 26 (IBM) software was used to perform the statistical analysis, and
the Saphiro–Wilk test and Levene test were employed for the evaluation of homogeneity
and variance, and normal distribution of samples, respectively. Student’s t-test was used
to compare means from two independent groups and ANOVA for multiple comparisons,
followed by Bonferroni or T3 Dunnet post-hoc, depending on the results of the Levene
test of homogeneity of variances. p < 0.05 was considered statistically significant. Data are
shown as mean ± standard deviation (SD).
3. Results
3.1. Size and Zeta Potential of SLNs and Vectors
Table 2 shows the average size, polydispersity index (PDI), and ζ-potential of the
SLNs. The particle size ranged from 93.3 to 307.8 nm and PDI values were lower than
0.3. The superficial particle charge ranged from +21.1 to +68.5 mV. Significant differences
(p < 0.001) were observed in terms of particle size and superficial charge among all SLNs.
SLNC showed the highest particle size and the lowest superficial charge, whereas SLNHM
showed the smallest size and the highest superficial charge. The Particle Size Distribution
Intensity Diagram of SLNHM has been included as an example in (Supplementary Material
Figure S1).
Table 2. Physical characterization of solid lipid nanoparticles (SLNs).
SLNs Size (nm) PDI ζ-Potential (mV)
SLNEE 198.7 ± 2.0 0.26 ± 0.01 +57.8 ± 1.7
SLNHM 93.3 ± 0.4 0.28 ± 0.01 +68.5 ± 0.7
SLNC 307.8 ± 3.5 0.17 ± 0.01 +21.1 ± 0.8
DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanoparticle prepared by emulsification-evaporation method.
SLNHM: solid lipid nanoparticle prepared by hot-melt emulsification method. SLNC: solid lipid nanoparticle
prepared by coacervation method. PDI: polydispersity index. Data are expressed as mean ± standard deviation;
n = 3.
Table 3 shows the size, PDI, and ζ-potential of the SLN-based vectors containing
CleanCapTM EGFP mRNA (5moU) or IL-10 mRNA customized by TriLink BioTechnologies.
All formulations were prepared with protamine (P). Moreover, an aqueous solution of
polysaccharide, either dextran (DX) or hyaluronic acid (HA), was incorporated into the
SLNEE and SLNHM vectors. Since SLNC vectors contain DEAE-dextran in their composition,
only HA was used to prepare the mRNA-HA-SLNC vector. The particle size of vectors
containing EGFP mRNA ranged from 132.3 to 348.4 nm, PDIs were lower than 0.4, and the
surface charge ranged from +9.5 to +43.9 mV. A PDI value less than 0.4 is related to the
homogeneity in the size of the particles of the sample and it demonstrates a monodisperse
sample population, which is considered acceptable for drug delivery [38]. Significant
differences (p < 0.001) in terms of size were observed in both mRNA-SLNHM formulations
and mRNA-HA-SLNC with respect to the rest of the formulations. Regarding the superficial
charge, significant differences (p < 0.001) were observed between SLNC vectors (with
the lowest superficial charge), as well as mRNA-DX-SLNEE (with the highest superficial
charge), with respect to the rest of the formulations. Particle Size Distribution Intensity
Diagram of mRNA-HA-SLNHM bearing CleanCapTM EGFP mRNA (5moU) has been
included as an example in (Supplementary Material Figure S2).
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Table 3. Physical characterization of mRNA-based vectors.
Size (nm) PDI ζ-Potential (mV)
CleanCapTM EGFP mRNA (5moU)
mRNA-DX-SLNEE 241.7 ± 4.8 0.29 ± 0.01 +43.9 ± 0.25
mRNA-HA-SLNEE 287.2 ± 1.8 0.36 ± 0.01 +37.7 ± 0.3
mRNA-DX-SLNHM 132.3 ± 1.9 0.25 ± 0.01 +38.0 ± 1.3
mRNA-HA-SLNHM 132.4 ± 1.6 0.20 ± 0.01 +32.7 ± 0.3
mRNA-SLNC 292.0 ± 1.2 0.17 ± 0.02 +9.5 ± 0.4
mRNA-HA-SLNC 348.4 ± 2.9 0.26 ± 0.01 +13.2 ± 0.6
IL-10 mRNA
mRNA-DX-SLNEE 180.1 ± 1.1 0.21 ± 0.00 +49.2 ± 0.3
mRNA-HA-SLNEE 199.4 ± 0.7 0.21 ± 0.00 +46.3 ± 0.1
mRNA-DX-SLNHM 116.9 ± 0.9 0.25 ± 0.00 +42.1 ± 2.0
mRNA-HA-SLNHM 121.3 ± 1.0 0.24 ± 0.00 +41.7 ± 0.2
mRNA-SLNC 242.8 ± 1.7 0.25 ± 0.01 +19.4 ± 0.9
mRNA-HA-SLNC 283.9 ± 4.6 0.26 ± 0.02 +19.5 ± 1.6
DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanoparticle prepared by emulsification-evaporation method. SLNHM: solid
lipid nanoparticle prepared by hot-melt emulsification method. SLNC: solid lipid nanoparticle prepared by coacervation method. PDI:
polydispersity index. Data are expressed as mean ± standard deviation; n = 3.
IL-10 mRNA vectors showed a smaller particle size than those prepared with GFP
mRNA, ranging from 116.9 to 283.9 nm, with a PDI lower than 0.3 and a superficial charge
from +19.4 to +49.2 mV. Significant differences (p < 0.001) were observed between the
vectors prepared with different SLNs with respect to the rest of the formulations in terms
of particle size. Regarding the superficial charge, significant differences (p < 0.001) were
observed between mRNA-SLNC and mRNA-HA-SLNC with respect to the others.
Table 4 shows the size, PDI, and ζ-potential of the SLN-based vectors containing either
plasmid pcDNA3-EGFP or plasmid pUNO1-hIL10. Only SLNHM were employed. All
formulations were prepared with P, DX or HA, and SLNs. The particle size of the vectors
bearing pcDNA3-EGFP plasmid ranged from 94.5 to 204.0 nm, PDIs were lower than 0.3,
and the surface charge ranged from +26.3 to +43.9 mV. Significant differences (p < 0.001)
were noticed with regard to particle size and ζ-potential between formulations. In the case
of pUNO1-hIL10 vectors, the particle size ranged from 101.1 to 193.7 nm, PDIs were less
than 0.3 except for pDNA-HA-SLNHM, which was 0.48. The superficial charge ranged
from +41.4 to +44.7 mV. Significant differences (p < 0.001) were reported in terms of size
between formulations.
Table 4. Physical characterization of pDNA-based vectors.
Size (nm) PDI ζ-Potential (mV)
Plasmid pcDNA3-EGFP
pDNA-DX-SLNHM 94.5 ± 1.0 0.27 ± 0.00 +43.9 ± 1.01
pDNA-HA-SLNHM 204.0 ± 2.8 0.25 ± 0.01 +26.3 ± 0.1
Plasmid pUNO1-hIL10
pDNA-DX-SLNHM 101.1 ± 1.1 0.27 ± 0.00 +44.7 ± 0.6
pDNA-HA-SLNHM 193.7 ± 15.1 0.48 ± 0.01 +41.4 ± 0.2
DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanoparticle prepared by emulsification-evaporation method. SLNHM: solid
lipid nanoparticle prepared by hot-melt emulsification method. SLNC: solid lipid nanoparticle prepared by coacervation method. PDI:
polydispersity index. Data are expressed as mean ± standard deviation; n = 3.
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No significant differences in particle size, PDI, or ζ-potential was observed when
SLNs were labelled with Nile Red (data not shown).
3.2. Agarose Gel Electrophoresis Assay
Figure 1 shows the ability of SLNHM and SLNC vectors to bind, protect, and release
mRNA (Figure 1A) and the capacity of SLNHM vectors to bind, protect, and release pDNA
(Figure 1B).
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Regarding the binding capacity, the absence of bands in both gels and the presence of
mRNA (Figure 1A) and pDNA (Figure 1B) on the loading wells indicate that nucleic acid
was completely bound to the vector and unable to migrate through the gel.
Differences in the protection capacity were observed according to the formulation.
Bands in the lanes corresponding to vectors prepared with SLNEE and SLNHM were
more intense and less faded than those prepared with SLNC; these data indicate a higher
protection degree of the nucleic acid. Moreover, the presence of the two bands in the SLNC
lanes indicates a lower capacity of protection.
In the case of pDNA vectors, both formulations were capable of protecting the nucleic
acid against DNase I digestion. All formulations were able to release pDNA after the
treatment with SDS.
3.3. pH Measurement
Table 5 shows the pH values of mRNA- and pDNA-based vectors formulated as eye
drops (1% PVA in HBS (Hanks’ Balanced Salt solution) pH = 7.4). The pH values ranged
from 7.13 to 7.44 and did not show significant differences depending on the formulations.
Table 5. pH measurements of mRNA- and pDNA-based vectors.
Sample pH
mRNA-DX-SLNEE 7.31 ± 0.04
mRNA-HA-SLNEE 7.20 ± 0.16
mRNA-DX-SLNHM 7.31 ± 0.04
mRNA-HA-SLNHM 7.44 ± 0.21
mRNA-SLNC 7.08 ± 0.29
mRNA-HA-SLNC 7.13 ± 0.11
pDNA-DX-SLNHM 7.39 ± 0.06
pDNA-HA-SLNHM 7.53 ± 0.02
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3.4. Cell Culture Studies
3.4.1. Transfection Efficacy and Cell Viability
Figure 2 shows the percentage of transfection and intensity of fluorescence of HCE-2
cells treated with the vectors containing mRNA GFP or pDNA at 37 ◦C and 4 ◦C.
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Figure 2. Flow cytometry analysis of transfection efficacy and intensity of fluorescence of HCE-2 cells
after the addition of SLNEE, SLNHM and SLNC vectors at 37 ◦C and 4 ◦C. Percentage of transfection
values correspond to the positive fluorescent GFP cells over the total cells. Log of intensity of
fluorescence indicates the average intensity of fluorescence per label d cell. Data re xpressed as
mean ± standard eviation; - ll t 37 ◦C and 4 ◦C 48 h
after administration of -based vectors. (B) Log of intensity of fluorescence of transfected HCE-
2 cells 48 h after administration of mRNA-based vectors. (C) Percentage of transfected HCE-2 cells at
37 ◦C and 4 ◦C 72 h after administration of pDNA-based vectors. (D) Log of intensity of fluorescence
of transfected HCE-2 cells 72 h after administration of pDNA-based vectors. # p < 0.05 with respect to
the same vector at 4 ◦C. DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanoparticle prepared
by emulsification-evaporation method. SLNHM: solid lipid nanoparticle prepared by hot-melt
emulsification method. SLNC: solid lipid nanoparticle prepared by coacervation method.
Amongst the mRNA-based formulations at 37 ◦C, the transfection percentage was
higher with the vectors prepared with SLNEE and SLNHM (Figure 2A) than with the vectors
prepared with SLNC. No significant differences were found between nanocarriers prepared
with SLNEE and SLNHM. With respect to the influence of temperature, the percentage of
transfection decreased significantly at 4 ◦C in all cases. Conversely, the fluorescent intensity
(Figure 2B) was similar regardless of the vectors employed and the operating temperature.
In the case of pDNA-based vectors, the percentage of transfected cells was similar
with the two formulations, approximately 8%. At 4 ◦C, the transfection efficacy was lower,
although the intensity of the fluorescence of pDNA-HA-SLNHM increased significantly.
Cell viability at 37 ◦C was approximately 98% for SLNEE and SLNHM, and 90% for
SLNC. At 4 ◦C, cell viability was approximately 98% for all formulations.
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3.4.2. Cellular Uptake
Figure 3 shows the efficacy of cellular uptake in HCE-2 cells at 37 ◦C and 4 ◦C after the
addition of mRNA- and pDNA-based vectors labelled with Nile Red. Cell internalization
was measured 2 h after the addition of the vectors to the cells cultures.
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3.4.3. Intracellular Disposition of the Vectors
Figure 4 shows the intracellular disposition of mRNA and pDNA in HCE-2 cells,
represented by the red fluorescence signal. Depending on the formulation, a difference in
the disposition of nucleic acid was observed.
The mRNA appeared dispersed along the cytoplasm when formulated in DX-SLNEE
and HA-SLNH (Figure 4A). However, in the case of the remaining vectors, it appears as
dots, indicating that it is more condensed.
The pDNA in the cells treated with the vectors appeared highly condensed and near
the nucleus (Figure 4B); no difference in the disposition of the pDNA was observed between
the two nanocarriers.
3.4.4. Quantification of IL-10
Figure 5 shows the levels of secreted and intracellular IL-10 in HCE-2 cells 48 h and
72 h after the addition of mRNA- and pDNA-based vectors, respectively. The mRNA-
vectors induced greater secretion of IL-10 than did the pDNA-based vectors. The basal
production of non-treated cells was not detectable. In the case of the mRNA-based vectors,
SLNEE formulations were the most effective, while SLNC vectors showed the lowest
secreted IL-10 levels.
Intracellular levels of the cytokine were close to 10 pg/mL with all formulations except
pDNA-HA-SLNHM, reaching 30 pg/mL (Supplementary Material Figure S3).
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Figure 4. Confocal microscopy analysis of intracellular disposition of mRNA- and pDNA-based
vectors 4 h after their addition in HCE-2 cells. (A) CleanCap™ Cyanine 5 EGFP mRNA (5moU)
vectors formulated with P, DX and HA. (B) pcDNA3-EGFP plasmid labeled with Label IT® Cy®5
vectors. Blue: nuclei labeled with DAPI. Red: fluorescence signal of nucleic acid labeled with Cy®5.
Magnification 60×. Scale bar: 15 µm. DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanopar-
ticl prepared by emulsification-evaporation method. SLNHM: solid lipid nanoparticle pr pared by
hot-melt emulsification method. SLNC: solid lipid nanoparticle prepared by coacervation method.
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capacity of transfection in the corneal epithelium. Figure 6 shows representative images 
of the corneas 48 h after being transfected with the different vectors. A 48 h time interval 
between administration of the formulations and animal sacrifice was initially used, in 
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Figure 5. Levels of secreted IL-10 by HCE-2 cells after the administration of SLN-based vectors
bearing IL-10 mRNA and pUNO1-hIL10 plasmid. (A) Concentration of secreted IL-10 48 h after
the administration of mRNA-based vectors. (B) Concentration of secreted IL-10 72 h after the
administration of pDNA-based vectors. ### p < 0.001 with respect to the mRNA-SLNEE and mRNA-
SLNC formulations. ** p < 0.01 with respect to the other formulation. *** p < 0.001 with respect to
the other formulation. DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanoparticle prepared
by emulsification-evaporation method. SLNHM: solid lipid nanoparticle prepared by hot-melt
emulsification method. SLNC: solid lipid nanoparticle prepared by coacervation method.
3.5. In Vivo Studies
3.5.1. In Vivo Transfection with mRNA and pDNA Encoding GFP
Vectors bearing CleanCapTM EGFP mRNA (5moU) or plasmid pcDNA3-EGFP com-
bined with PVA were topically administered as eye drops to mice in order to assess the
capacity of transfection in the corneal epithelium. Figure 6 shows representative images
of the corneas 48 h after being transfected with the different vectors. A 48 h time interval
between administration of the formulations and animal sacrifice was initially used, in order
to compare the effects of fast acting mRNA and slow acting pDNA vectors.
GFP was detected in 100% of the sections analyzed. All formulations were able to
transfect and produce GFP in the corneal epithelium. GFP produced by naked mRNA was
difficult to observe, whereas the intensity of fluorescence of GFP was higher when mRNA
was formulated in the vectors.
GFP produced by mRNA-DX-SLNEE and mRNA-DX-SLNHM was localized continu-
ously along the epithelium surface. In the case of mRNA-HA-SLNEE, mRNA-HA-SLNHM,
and mRNA-SLNC, uninterrupted segments of GFP were observed. In contrast, GFP in the
corneas transfected with mRNA-HA-SLNC was localized discontinuously.
Regarding transfection of the corneas with the nanocarriers prepared with pDNA,
GFP was detected in a wider area with pDNA-HA-SLNHM than with pDNA-DX- SLNHM.
pDNA-based formulations were used as controls for the mRNA-based ones; naked pDNA
(GFP and IL-10) was previously evaluated [32].
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Figure 6. I i o l t f ti in mice 48 h after the administration of mRNA- and pDNA-vectors encoding GFP with
the viscosifier PVA (63×). Blue: nuclei stained with DAPI. Green: GFP detected by immunofluorescence with the secondary
antibody labeled with Alexa Fluor 488. Scale bar: 20 µm. DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanoparticle
prepared by emulsification-evaporation method. SLNHM: solid lipid nanoparticle prepared by hot-melt emulsification
method. SLNC: solid lipid nanoparticle prepared by coacervation method.
Furthermore, by analyzing the corneas of the mice treated with selected formulations
(mRNA-HA-SLNEE) after 24 h, it was observed that GFP was detected in a larger surface
area and with a higher intensity of fluorescence than after 48 h (Supplementary Material
Figure S4). Considering these promising results with mRNA-based vectors, indicating a
faster onset of action than initially expected, the corneas treated with the vectors bearing
mRNA-IL-10 were evaluated at 24 h post administration. Indeed, a 24 h timeframe, which
is required because a quick expression of IL-10 would help to deal with the progression of
the inflammatory disease, would be too short for pDNA expression.
3.5.2. In Vivo Transfection with mRNA Encoding Human IL-10
mRNA vectors enco ing IL-10 viscosized with PVA were administered to mice as eye
drops. Th transfection efficacy of vectors was analyzed qualitatively 24 h after the last
administratio (Figure 7).
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Figure 7. In vivo corneal transfection in mice 24 h after the admin stration of mRNA-vectors encoding human IL-10 with the
viscosifier PVA (63×). Blue: nuclei stained with DAPI. Green:IL-10 detected by immunofluorescence with the secondary
antibody labeled with Alexa Fluor 488. Scale bar: 20 µm. DX: dextran; HA: hyaluronic acid; SLNEE: solid lipid nanoparticle
prepared by emulsification-evaporation method. SLNHM: solid lipid nanoparticle prepared by hot-melt emulsification
method. SLNC: solid lipid nanoparticle prepared by coacervation method.
IL-10 was observed continuously along the corneal epithelium in all analyzed sections.
The intensity of the fluorescence signal was higher when the corneas were treated with the
nanosystems than in the case of the naked mRNA. Slight differences were found among
the different vectors, although with mRNA-DX-SLNEE and mRNA-HA-SLNC, IL-10 was
also detected in deeper corneal layers underlying the epithelium (arrows in magnification).
4. Discussion
The development of new nanomedicine products for mRNA-based therapies has
emerged as an attractive and promising tool in the field of advanced therapies. In this study,
we have developed nanovectors based on SLNs for nucleic acid delivery. Three different
methods were used to prepare the SLNs: SLNEE, prepared by evaporation/emulsification,
SLNHM obtained by hot-melt emulsification, and SLNC prepared by coacervation.
The preparation method influenced the physicochemical features of the SLNs, in terms
of particle size and surface charge. In particular, SLNEE and SLNHM, made up with the
same chemical components but prepared by different methods, varied in particle size.
Indeed, it ranged from 90 nm in the case of the hot emulsification procedure, which avoids
the use of organic solvents, but involves a high operating temperature, to 200 nm in the
case of the evaporation/solvent method. The solvent-free coacervation method, which
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exploits different compositions compared to the previously mentioned techniques, led to
the highest particle size.
The final vectors were made up by electrostatic interactions among SLN, nucleic
acid (mRNA or pDNA), and different ligands. Differences regarding the physicochemical
characteristics of the SLN may lead to variations in the arrangement of the remaining com-
ponents, since they are adsorbed on the SLN’s surface to form the final vector. Therefore,
the transfection capacity can be influenced. Firstly, the genetic material was condensed
with P, which contributes to binding and protecting the nucleic acid extra and intracel-
lularly due to its cationic character [39,40]. Secondly, if required, HA or DX were added;
these polysaccharides influence the interactions with the target cells and the intracellular
disposition of the nucleic acid [41–43]. An additional advantage of the inclusion of one of
these polysaccharides is long-term stability for mRNA-SLN-based formulations [33].
For corneal transfection, small-sized particles between 10 and 1000 nm reduce eye irri-
tability after topical administrations. Moreover, they show mucoadhesive properties, which
help to prolong the residence time and, consequently, to increase the drug bioavailability in
the ocular tissues [29,44]. The vectors prepared in our work showed a mean size lower than
300 nm and a positive superficial charge, which facilitates cellular uptake [30] and prolongs
the retention time at the corneal epithelium, thanks to the electrostatic interactions with the
negatively charged ocular surface [45].
A successful transfection depends upon the balance between the protection provided
by the nanosystem to the nucleic acid against degradation, and its capacity to unpack
and release the same inside the cell. The preparation method and the composition of the
formulations, especially the presence of different ligands, have an important influence
on the mRNA condensation and consequently, on the binding, protection, and release
from the vector. Electrophoresis on agarose gel (Figure 1) showed that the SLNc vectors
presented a weak protection capacity against external agents, and a low release ability.
In the case of mRNA-SLNEE and mRNA-SLNHM vectors, differences in the condensation
degree were observed (Figure 4). Nevertheless, both formulations protected and released
the mRNA effectively (Figure 1). By contrast, no differences in condensation, protection,
release capacity, and intracellular disposition of the genetic material were observed in
pDNA vectors. Therefore, mRNA seems to be more sensitive to the formulation-related
factors than does pDNA.
The interaction between the formulation components and target cells condition the
internalization process, and therefore, the intracellular disposition, the endosomal escape
and, consequently, the transfection capacity of the systems [41,43,46]. The multi-component
nanosystem developed in this work could be adapted to overpass the limiting barriers at
the intracellular level, providing an appropriate nucleic acid packaging in the target cells.
Endocytosis is the most common mechanism used by SLNs to enter inside the cells. It is an
energy- and temperature-dependent process, associated with endosomal/lysosomal path-
ways of cellular trafficking. Depending on the lipid composition and the physicochemical
characteristics of the non-viral vector, the predominant pathway may be different [47,48].
It is well-known that all energy-dependent uptake mechanisms are inhibited by cold tem-
peratures [49]. In the present work, the influence of temperature (37 ◦C vs. 4 ◦C) on
cellular uptake and transfection efficacy was studied in the HCE-2 cells. Cellular uptake
remained stable at both temperatures, which indicates that not only energy-dependent but
also energy-independent entry mechanisms are undertaken. Conversely, the percentage
of transfected cells decreased significantly at 4 ◦C, whereas the intensity of fluorescence,
indicative of the amount of protein produced by transfected cells, remained almost stable.
Therefore, at cold temperatures the few transfected cells are able to produce a higher
amount of protein. These results show that the transfection of HCE-2 cells is favoured
by energy-dependent mechanisms, although the production of protein seems to be more
efficient when the vectors are taken up by energy-independent mechanisms.
The transfection capacity of mRNA- and pDNA-based vectors was similar in terms
of transfected cells and intensity of fluorescence (Figure 2). Contrarily to pDNA, mRNA
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bypasses one of most limiting steps: it does not need to reach the nucleus to transfect, and
therefore, it is expected to lead to a faster transfection rate. Noteworthy, our results seem to
indicate that the bottleneck for a successful transfection in corneal epithelial cells is before
the nuclear entry; as a consequence, the intra-cytoplasmic behaviour of our nanosystems
seems to be the limiting step for the transfection.
Transfection studies with the nanovectors bearing pDNA or mRNA encoding the anti-
inflammatory cytokine IL-10 were also carried out in HCE-2 cells. The IL-10 was measured
in the culture media and at the intracellular level. The mRNA vectors most efficient in terms
of IL-10 production were those containing the SLNs prepared by the solvent/evaporation
method. For the same kind of SLNs (SLNEE or SLNHM), those containing DX were more
effective than those containing HA. The mRNA-vectors, including the SLNs prepared by
coacervation, hardly produced IL-10. The levels of IL-10 secreted by cells treated with
the vectors prepared with SLNHM and either mRNA or pDNA were similar (Figure 5).
It is expected that levels over 0.8 ng/mL of IL-10 would exert the anti-inflammatory
effect [50]. In previous works, we showed that SLNs-based systems bearing pDNA were
able to produce up to 10 ng/mL of IL-10 in HCE-2 cells [8]. In our case, the IL-10 levels
obtained with mRNA-SLNEE were higher; in particular, the most effective formulation,
mRNA-DX-SLNEE, showed IL-10 levels almost three-folds higher.
The formulation of nanodelivery systems plays a crucial role in the development of
medicinal products based on gene therapy, and specifically, in ocular gene therapy. An
optimal ophthalmic drug formulation should comply to an adequate bioavailability, an
increased permeability, an improved stability against degradation, a prolonged retention
on the eye surface, and an augmented interaction with the cornea and targeted deliv-
ery [51]. Indeed, due to the pseudoplastic properties of the tear fluid, the inclusion of
thickening agents could be advantageous in order to increase the corneal retention time
and ocular bioavailability [52]. For the in vivo studies, the thickening agent PVA was added
to the vectors. The non-ionic and synthetic biodegradable hydrophilic polymer PVA [53]
is approved by the FDA for use in ophthalmic formulations [54]. PVA has been widely
used because of its muco-mimetic properties, high water retention capacity, oxygen per-
meability, and low toxicity [55]. These properties confer to our nanosystems the ability to
increase the residence time, and consequently improve the ocular bioavailability, reducing
the drainage from lachrymal fluid [56,57]. In early studies, our group showed that the
combination of SLN-based vectors with PVA provided a higher retention on the cornea [32].
Ophthalmic formulations should have the pH of the lacrimal fluid, or a pH within the
range of the ocular comfort range, in order to ensure a good tolerance [58,59]. The ocular
pH ranges from 6.6 to 7.8; it is reported that a pH value of an ocular preparation ranged
outside 5.0-8.5 causes extra lachrymation and decreases the ocular residence time [60]. Our
formulations showed pH values within the ocular tolerance range, from 7.1 to 7.5 (Table 5).
In vivo studies in mice were first carried out to evaluate the formulations containing
mRNA or pDNA for GFP expression. Since GFP, once produced, remains at the intracellular
level, it allowed us to identify the corneal layers where transfection occurs, after the instilla-
tion on the mice ocular surface with these vectors. Since the cornea is a complex structure,
mRNA-delivery systems are engineered to induce the therapeutic protein expression in the
cornea, specifically in the stratified and renewable epithelial layer, where a high number
of cells can be transfected. Another alternative could be the transfection of the innermost
layer of the cornea, the endothelial layer, associated with a difficult accessibility. Indeed,
this layer contains a low number of cells that do not undergo division and gene expression
could be maintained for longer times. To this aim, DNA could be most advantageous, since
it provides a more persistent transgene production than mRNA. However, although we
have previously shown the capacity of DNA-based formulations to transfect the cornea [8],
mRNA possesses several advantages that could make it a better option for corneal inflam-
mation management. Indeed, mRNA shows a better safety profile than DNA; the encoded
protein is earlier produced, and its expression is transitory, which makes the behaviour of
this molecule easier to predict. Moreover, taking into account that the corneal epithelium
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only needs 7 to 14 days to achieve a complete renewal [61], a short-term expression of the
protein is required.
All mRNA-based formulations included in this experimental work transfected the
cornea in vivo and showed a higher intensity of fluorescence than naked mRNA. Thus, the
SLNs resulted necessary to obtain a high transfection efficiency. These formulations were
able to transfect only the epithelial cells but not the inner layers of the cornea, regardless of
their different particle size. The intensity of fluorescence of GFP observed in the HCE-2
cells in vitro, representative of the protein production, was similar for all formulations, and
it seems to correlate better with the in vivo results than with the percentage of transfected
cells in vitro. Nevertheless, the lack of a strict correlation between in vitro and in vivo
studies [62–65] highlights the necessity to perform the latter ones at the earliest phases
of the pharmaceutical development process, in order to perform adequate selection and
optimization of candidate formulations.
Finally, we evaluated the capacity of our formulations to induce the production of the
anti-inflammatory cytokine IL-10 [51]. In view of the fact that IL-10 is a secreted protein,
it may be produced in the epithelial corneal cells and diffuse through the cornea to reach
deeper layers. Moreover, for corneal inflammation management, a quick expression of IL-
10 would help to deal with the progression of the disease. In this context, we administered
the formulations for 3 days and, 24 h after the last administration, the presence of IL-10
in the cornea was assessed. When mice were treated with an mRNA-DX-SLNEE vector,
the best performing formulation in in vitro experiments in HCE-2 cells (Figure 5), the
interleukin was even observed in the deeper layers of the epithelium (Figure 7). mRNA-
HA-SLNC vectors also showed a high capacity to produce IL-10, despite the low efficacy
observed in vitro. It should be considered that the transfection efficacy of the nanovectors
could be increased in inflamed corneas, as the histological structure of corneal layers
would be altered and disorganized, resulting in a potentially increased permeation of
the nanosystems into the tissue. Within this concern, in previous studies with SLN-based
nanosystem containing pDNA as the nucleic acid, vectors prepared with the polysaccharide
HA showed the highest transfection efficacy [32]. pDNA and mRNA differ not only in
their physico-chemical characteristics, but also in terms of their intracellular barriers to
overcome in order to achieve protein production. Our results confirm the necessity of the
adaptation of the nanovector to the target cells and to the nature of the nucleic acid, in
order to obtain an effective transfection.
5. Conclusions
The nature of the nucleic acid and the target cell are key points for the design and
optimization of nanosystems aimed at ocular gene delivery, with mRNA being more
sensitive to the formulation-related factors than pDNA. Nanomedicinal products design is
based, initially, on in vitro studies. We have demonstrated that the HCE-2 cells’ transfection
is favoured by energy-dependent mechanisms, but the production of protein is more
efficient when the vectors are taken up by energy-independent mechanisms. However, the
lack of correlation observed between in vitro and in vivo assays has highlighted the necessity
to perform in vivo studies at the earliest phases of the pharmaceutical development of
nucleic acid delivery systems. In the present work, SLNs allowed the ability to obtain a
high transfection efficiency in vivo. Therefore, topical administration to mice of eye drops
containing mRNA formulated in SLNs has shown to be a feasible strategy to tackle corneal
inflammation by de novo fast IL-10 production from corneal epithelial cells.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13091472/s1, Figure S1: Particle Size Distribution Intensity Diagram of SLNHM.
Figure S2: Particle Size Distribution Intensity Diagram of mRNA-HA-SLNHM bearing CleanCapTM
EGFP mRNA (5moU). Figure S3: Intracellular levels of IL-10 in HCE-2 cells after the administration
of SLN-based vectors bearing IL-10 mRNA and pUNO1-hIL10 plasmid. Figure S4: In vivo corneal
transfection in wild type mice 24 h and 48 h after the administration of mRNA-HA-SLNEE with PVA
(63×).
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